Says discontinuing ABBV-154 due to risk benefit profile. Comments taken from Q1 earnings conference call.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Abbvie Earnings Update: Did it Beat Estimate Forecasts?
- AbbVie reports Q1 global Humira revenue $3.54B, down 25.2% on reported basis
- AbbVie Reports First-Quarter 2023 Financial Results
- AbbVie raises FY23 adjusted EPS view to $10.72-$11.12 from $10.62-$11.02
- AbbVie reports Q1 adjusted EPS $2.46, consensus $2.46
